These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 26811092)

  • 1. Remember Keppra: seizure control with subcutaneous levetiracetam infusion.
    Murray-Brown FL; Stewart A
    BMJ Support Palliat Care; 2016 Mar; 6(1):12-3. PubMed ID: 26811092
    [No Abstract]   [Full Text] [Related]  

  • 2. Continuous subcutaneous levetiracetam in the management of seizures at the end of life: a case report.
    Wells GH; Mason LD; Foreman E; Chambers J
    Age Ageing; 2016 Mar; 45(2):321-2. PubMed ID: 26744359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Continuous subcutaneous use of levetiracetam: a retrospective review of tolerability and clinical effects.
    Rémi C; Lorenzl S; Vyhnalek B; Rastorfer K; Feddersen B
    J Pain Palliat Care Pharmacother; 2014 Dec; 28(4):371-7. PubMed ID: 25313924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subcutaneous levetiracetam for the management of seizures at the end of life.
    Sutherland AE; Curtin J; Bradley V; Bush O; Presswood M; Hedges V; Naessens K
    BMJ Support Palliat Care; 2018 Jun; 8(2):129-135. PubMed ID: 28735270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuous subcutaneous levetiracetam in end-of-life care.
    Furtado I; Gonçalves F; Gonçalves J; Neves J
    BMJ Case Rep; 2018 Jan; 2018():. PubMed ID: 29351934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subcutaneous Bolus Infusions of Undiluted Levetiracetam for End-of-Life Patients: Two Cases.
    Skov K; Lyager A
    J Pain Palliat Care Pharmacother; 2024 Jun; 38(2):138-142. PubMed ID: 38346166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interactions of levetiracetam with carbamazepine, phenytoin, topiramate and vigabatrin in the mouse 6Hz psychomotor seizure model - a type II isobolographic analysis.
    Florek-Luszczki M; Wlaz A; Luszczki JJ
    Eur J Pharmacol; 2014 Jan; 723():410-8. PubMed ID: 24211788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Seizure risk in brain tumor patients with conversion to generic levetiracetam.
    Armstrong TS; Choi S; Walker J; Gilbert MR
    J Neurooncol; 2010 May; 98(1):137-41. PubMed ID: 19936624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous levetiracetam in children with seizures: a prospective safety study.
    Ng YT; Hastriter EV; Cardenas JF; Khoury EM; Chapman KE
    J Child Neurol; 2010 May; 25(5):551-5. PubMed ID: 20413804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generic substitution of levetiracetam resulting in increased incidence of breakthrough seizures.
    Fitzgerald CL; Jacobson MP
    Ann Pharmacother; 2011 May; 45(5):e27. PubMed ID: 21521860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of intermittent levetiracetam dosing in a patient with refractory daily seizures.
    Friedman D; French JA
    Neurology; 2006 Feb; 66(4):590-1. PubMed ID: 16505320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of levetiracetam in refractory status epilepticus.
    Patel NC; Landan IR; Levin J; Szaflarski J; Wilner AN
    Seizure; 2006 Apr; 15(3):137-41. PubMed ID: 16426869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacology and clinical results of levetiracetam (E Keppra(®) Tablets), a new antiepileptic drug].
    Ishii Y; Tanaka T
    Nihon Yakurigaku Zasshi; 2011 Feb; 137(2):95-102. PubMed ID: 21321459
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy and safety of levetiracetam as an add-on therapy in children aged less than 4 years with refractory epilepsy.
    Li S; Cao J; Xiao N; Cai F
    J Child Neurol; 2010 May; 25(5):609-13. PubMed ID: 19779208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Subcutaneous administration of levetiracetam in geriatrics].
    Maison O; De la Gastine B; Peter-Derex L; Berger C; Goutelle S
    Rev Neurol (Paris); 2015 Apr; 171(4):398-9. PubMed ID: 25847398
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of levetiracetam in patients with epilepsy and interictal epileptiform discharges.
    Stodieck S; Steinhoff BJ; Kolmsee S; van Rijckevorsel K
    Seizure; 2001 Dec; 10(8):583-7. PubMed ID: 11792161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effect of levetiracetam on intractable secondarily generalized seizure and depression].
    Hayashi T; Inoue K; Shinoda J
    Brain Nerve; 2012 Mar; 64(3):303-7. PubMed ID: 22402725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous levetiracetam for treatment of neonatal seizures.
    Rakshasbhuvankar A; Rao S; Kohan R; Simmer K; Nagarajan L
    J Clin Neurosci; 2013 Aug; 20(8):1165-7. PubMed ID: 23664133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levetiracetam in submaximal subcutaneous pentylentetrazol-induced seizures in rats.
    Coppola G; Arcieri S; D'Aniello A; Messana T; Verrotti A; Signoriello G; Pascotto A
    Seizure; 2010 Jun; 19(5):296-9. PubMed ID: 20399683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Seizure freedom is not adversely affected by early discontinuation of concomitant anti-epileptic drugs in the EULEV cohort of levetiracetam users.
    Droz-Perroteau C; Marchal C; Dureau-Pournin C; Lassalle R; Jové J; Robinson P; Lavernhe G; Vespignani H; Moore N; Fourrier-Réglat A;
    Pharmacoepidemiol Drug Saf; 2012 Nov; 21(11):1183-9. PubMed ID: 22972760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.